Optimizing labeling conditions of 213Bi somatostatin analogues for receptor mediated process in preclinical models

The use of alpha emitters as a therapeutic nuclide for cancer therapy becomes more interesting in the field of Nuclear Medicine. 213Bi (t1/2 = 45.6 min) is one of the most widely used alpha emitter. For receptor-mediated processes high specific activity (SA, expressed in MBq per mass ligand) is required, since the uptake is dependent on the amounts of receptors available on the tumor. However due to the radiochemical limitation; e.g. high osmolarity, large reaction volume, etc., applications to in vitro and in vivo for this processes, especially in a mouse model (